Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report

doi:10.12998/wjcc.v10.i35.13122

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2791)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

122

WORD

HTML

1325

Figures (1-3)

611

Tables (1-1)

172

Sum=2262

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

172

Download

357

Sum=529

Dec 16, 2022 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Dec 16, 2022; 10(35): 13122-13128
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.13122

Open in New Tab Full Size Figure Download Figure

Figure 1 Changes in hemoglobin, hematocrit and blood lipids before and after oral administration of Roxadustat. A: Changes in hemoglobin and hematocrit (January 10, 2020); B: Changes in blood lipids (January 2020). HGB: Hemoglobin and HCT: Hematocrit; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; TC: Total cholesterol.

Open in New Tab Full Size Figure Download Figure

Figure 2 Changes in Ferritin, Transferrinsaturation, and serum potassium levels before and after (January 2020) the oral administration of Roxadustat. A: Changes in Ferritin; B: Changes in Transferrinsaturation; C: Changes in serum potassium levels. FER: Ferritin; TSAT: Transferrinsaturation.

Open in New Tab Full Size Figure Download Figure

Figure 3 Magnetic resonance imaging: Encephalatrophy (June 2022).

Citation: Xu C, Luo DG, Liu ZY, Yang D, Wang DD, Xu YZ, Yang J, Fu B, Qi AR. Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report . World J Clin Cases 2022; 10(35): 13122-13128
URL: https://www.wjgnet.com/2307-8960/full/v10/i35/13122.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i35.13122